Vasopressin
Arginine Vasopressin (AVP)
Evidence & Status
- FDA Approved
- Strong Human Evidence
- Strong
At a Glance
Native arginine vasopressin with VASOSTRICT label-scoped U.S. use.
Plain English
This record limits product information to the VASOSTRICT labeled intravenous adult vasodilatory-shock scope.
Overview
Native arginine vasopressin is a nonapeptide. This record is limited to current VASOSTRICT label scope: intravenous use in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
Research Summary
Route, preparation, dosing, warnings, safety, and storage are label-specific. This record does not include generic diabetes-insipidus approval, intranasal, cognitive, desmopressin, WADA, or universal half-life claims.
Research Areas
- Memory consolidation
- Social cognition and behavior
- Stress response
- Central diabetes insipidus
- Vasodilatory/septic shock
- Emotional processing
Legal Status by Region
- United States
- VASOSTRICT is labeled for intravenous use in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
- United Kingdom
- MHRA-approved prescription drug
- Australia
- TGA-approved prescription drug
- Canada
- Health Canada-approved
Citations & Sources
- VASOSTRICT (vasopressin injection) — Prescribing Information
Regulatory NDA 204485